19 May 2013
Keywords: mgi/helsinn, aloxi, meets, ph, iii, endpoints, drugmaker
Article | 22 December 2006
US drugmaker MGI Pharma and partner Helsinn Healthcare SA, a privately-held Swiss pharmaceutical group, have completed two Phase III
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 December 2006
17 May 2013
© 2013 thepharmaletter.com